ALK2403

ALK2403 is an orally bioavailable small molecule analgesic being developed by Alikon (Hefei) Pharmaceutical Technology for the treatment of acute pain. It functions as a selective inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene). Nav1.8 is primarily expressed in peripheral sensory neurons (nociceptors) and plays a critical role in the generation and transmission of pain signals. By selectively blocking this channel, ALK2403 aims to provide effective pain relief while minimizing the central nervous system side effects typically associated with non-selective sodium channel blockers or opioid analgesics. As of early 2026, the drug is in Phase 1 clinical development, with studies focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers, including assessments of food effects and cardiac safety (CQT assessment).